A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
Jonathan W. Riess(University of California Davis Medical Center), Karen Kelly(Cancer Research Center), Lu Qian(Wenzhou Medical University), Megan Baumgart(University of Rochester), David R. Gandara(University of California, Davis), Larry Corum(Olathe Medical Center), Mary W. Redman(Fred Hutch Cancer Center), Aruna Gowda, Paul Wheatley‐Price(University of Ottawa), Bryan A. Faller(Missouri Baptist Medical Center), Gordan Srkalović(Regional Cancer Center), Katherine Minichiello(Fred Hutch Cancer Center), Liza C. Villaruz(University of Pittsburgh Medical Center), Raymond U. Osarogiagbon, Roy S. Herbst(Smilow Cancer Hospital)
Cited by 10
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k